Peptide News Digest

Semaglutide and Other Prescriptions in Denmark, GLP-1s and Depression in Medicare, a Spider Venom Peptide for Breast Cancer

Danish semaglutide users filled fewer asthma and pain prescriptions but more anxiety drugs, and Medicare data tie GLP-1s to more depression, less dementia.

5 stories · Covering research

Editor's Note

Sunday's two GLP-1 papers looked past weight to everything else people take and feel. In Denmark, 189,392 people who started semaglutide for weight management filled fewer prescriptions for asthma, pain, depression, and skin conditions than their earlier trends predicted, but more for anxiety, and that rise was still there two years later. An NIH analysis of Medicare enrollees with type 2 diabetes found GLP-1 drugs linked to slightly more depression and fewer substance use disorders, dementia, and self-harm, with the pattern changing by how the drug was added to treatment; the authors caution that baseline differences may explain part of it. Outside GLP-1 drugs, a Brazilian team found a peptide from the Brazilian wandering spider slowed breast tumors in mice and worked better with doxorubicin, a Beijing team built PD-L1-targeting peptide nanofibers that combine heat treatment with immune checkpoint blocking, and an Innsbruck review made the case for dry reverse micelles as a way to deliver peptides by mouth.

Research

After Starting Semaglutide for Weight Loss, 189,392 Danes Filled Fewer Prescriptions for Asthma, Pain, and Depression but More for Anxiety

University of Southern Denmark researchers reported in Diabetes, Obesity and Metabolism on October 25, 2026 a nationwide interrupted time-series study of adults who started semaglutide for weight management between December 2022 and December 2024, comparing prescriptions in the 12 months after with trends from the 24 months before. At 12 months, use was lower than projected for asthma drugs (rate ratio 0.82), topical steroids (0.91), painkillers (0.93), antidepressants (0.93), and topical antifungals (0.92), and blood pressure drugs rose more slowly than expected (0.92). Anxiety medication use rose (1.16) and stayed elevated at two years; a similar drop in glucose-lowering drugs also appeared in a comparison group, so that change may not be due to semaglutide.

#semaglutide #wegovy #real-world-evidence #mental-health
Research

NIH Medicare Analysis Ties GLP-1 Drugs to Slightly More Depression but Fewer Substance Use Disorders, Dementia, and Self-Harm in Type 2 Diabetes

Researchers at the National Library of Medicine's intramural research division reported in Diabetes, Obesity and Metabolism on October 25, 2026 a propensity-matched Medicare claims study comparing GLP-1 drugs with other second-line diabetes medicines across eight neuropsychiatric outcomes. GLP-1 use was linked to a small rise in overall psychiatric disorders (hazard ratio 1.04, 1.7 extra events per 1,000 person-years) and in depression (1.11, 3.0 extra), and to fewer substance use disorders (0.84), dementia diagnoses (0.87), and suicidal or self-harm events (0.81). Risks were higher when a GLP-1 was used alone or as an escalation and lower or neutral when patients switched to or added one, which the authors say may reflect baseline differences between patients rather than the drug.

#glp-1 #depression #medicare #type-2-diabetes #mental-health
Research

UNICAMP Team's Brazilian Wandering Spider Peptide LW-9 Slows Breast Tumors in Mice and Boosts Doxorubicin by Lowering PD-L1

Researchers at Brazil's State University of Campinas (UNICAMP) reported in Immunology on October 25, 2026 that LW-9, a peptide isolated from the venom of the Brazilian wandering spider Phoneutria nigriventer, delayed tumor growth in mice with EO771 breast tumors, with a stronger effect combined with the chemotherapy drug doxorubicin. At 1 µg/kg it caused no significant changes in liver or kidney markers, and mice given it with doxorubicin ate more and held their weight better than mice on doxorubicin alone. Tumors in the combination group had less PD-L1 and more T cells, including GITR-positive T cells; the work is in mice.

#venom-peptides #breast-cancer #peptide-oncology #preclinical
Research

Peking Union Medical College Team's PD-L1-Binding Peptide Nanofibers Pair Mild Heat Therapy With Checkpoint Blockade in Animal Tumors

Researchers at Peking Union Medical College Hospital and the Beijing Institute of Technology reported in Advanced Science on October 25, 2026 carrier-free nanofibers that self-assemble from a nine-amino-acid peptide that binds PD-L1 on tumor cells and a near-infrared heat-producing agent. In tumor-bearing animals, the fibers combined with near-infrared light activated the immune environment inside tumors and slowed growth with less immune-related toxicity. Because the heat treatment switched on a survival pathway in tumor cells (HSP70/AKT/mTOR), adding the mTOR inhibitor rapamycin further improved results and reduced recurrence.

#peptide-oncology #cancer-immunotherapy #drug-delivery #preclinical
Research

Innsbruck Review Argues 'Dry' Reverse Micelles With Under 1% Water Could Carry Peptide Drugs Through the Gut

Pharmaceutical scientists at the University of Innsbruck in Austria reviewed in Small on October 24, 2026 reverse micelles, tiny droplets with a water-loving core inside an oily shell, as carriers for oral peptide and protein drugs. They argue that newer dry reverse micelles, with internal water below 1%, avoid the instability of older water-rich versions while protecting peptides from digestive enzymes and helping them cross the gut lining. The authors say animal studies show oral bioavailability comparable to or better than other approaches such as hydrophobic ion pairing in selected systems; the paper is a review, not new data.

#oral-peptides #drug-delivery

Related Guides